Johan Vansteenkiste
KU Leuven · Department of Pulmonology (Respiratory Tumor Unit), University Hospital Gasthuisberg, Catholic University Leuven, Belgium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Johan Vansteenkiste as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:46 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03970746 · Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLCPDC*line Pharma SAS · active not recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT00349089 · Trial on Refinement of Early Stage Lung Cancer Adjuvant TherapyThoraxklinik-Heidelberg gGmbH · completed · Non Small Cell Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:46 UTC. The ranking covers the 200 most relevant of 91 PubMed records, and a shared surname and initials can bring in a namesake. All 91 on PubMed
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20184,615 citationsRCR 168.8
- Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.J Clin Oncol · 20082,676 citationsRCR 61.7
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med · 20202,543 citationsRCR 114.6
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].J Clin Oncol · 20032,432 citationsRCR 47.9
- 2,386 citationsRCR 73.9
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med · 20182,335 citationsRCR 81.4
- Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.N Engl J Med · 20041,902 citationsRCR 41.0
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.J Clin Oncol · 20221,268 citationsRCR 88.1
- Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med · 20141,179 citationsRCR 32.9
- 815 citationsRCR 33.3